Colin Vale, MD

Colin Vale, MD, is an assistant professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine

Articles by Colin Vale, MD

Colin Vale, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

ByColin Vale, MD

March 18th 2026

Dr Vale discusses data from a phase 2 trial evaluating blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Dr Vale on Efficacy Data for Blinatumomab Plus Ponatinib in Ph+ B-ALL

ByColin Vale, MD

March 18th 2026

Colin Vale, MD, discusses long-term efficacy data for blinatumomab and ponatinib in Ph+ B-ALL and significance of achieving remission without procedures.

JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis

ByColin Vale, MD,Anthony M Hunter, MD

September 12th 2023

Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.

Colin Vale, MD

Articles by Colin Vale, MD

Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

Dr Vale on Efficacy Data for Blinatumomab Plus Ponatinib in Ph+ B-ALL

JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis

Latest Updated Articles

Trending on OncLive

Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA

Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma

Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma

FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification